Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
119.45
-1.32 (-1.09%)
At close: Jun 13, 2025, 4:00 PM
120.78
+1.33 (1.11%)
After-hours: Jun 13, 2025, 7:34 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.62B in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
4.41
Revenue / Employee
$701,369
Employees
75,883
Market Cap
234.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
NVS News
- 3 days ago - Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder - Benzinga
- 3 days ago - Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH - GlobeNewsWire
- 13 days ago - Novartis' Pluvicto shown to slow prostate cancer in earlier setting - Reuters
- 13 days ago - Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial - WSJ
- 13 days ago - Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer - GlobeNewsWire
- 19 days ago - Novartis announces commencement of tender offer to acquire Regulus Therapeutics - GlobeNewsWire
- 26 days ago - If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition) - Seeking Alpha
- 4 weeks ago - New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline - GlobeNewsWire